preclinical research

Acesis BioMed is a Colorado (USA) and London (UK) based biomedical company operating through Acesis Holdings Corporation and its subsidiaries Acesis Biomed US, Inc. and Acesis Biomed Ltd. It develops a platform of oral drug candidates for metabolic and endocrine disorders, initially focusing on male hypogonadism (low T) and related co-morbidities. Its proprietary first-in-class T peptide modulator is designed as a non-steroid alternative to Testosterone Replacement Therapy.

drug developmentmultigram-scale drug productionpeptide drug designR&D via academic centers and CROs

Alevian is a preclinical-stage biotech developing regenerative therapeutics that target biological mechanisms promoting repair and regeneration. Its lead program, ALE-001, is an engineered recombinant form of GDF11 designed to treat acute ischemic stroke by reducing inflammation, promoting neovascularization, stimulating neurogenesis, and improving functional recovery, with a treatment window extending to 3 days. ALE-001 is progressing toward first-in-human studies, with additional programs in intracerebral hemorrhage, traumatic brain injury, chronic str

biologics developmentGDF11 signaling pathway researchtranslational research

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The company leverages its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies to create therapeutic candidates designed to improve outcomes for cancer patients.

bispecific and trispecific immunotherapy developmentclinical developmentimmuno-oncology drug developmentproprietary ADAPTIR and ADAPTIR-FLEX platforms

Archeus Technologies is a radiopharmaceutical company developing differentiated radiopharmaceutical therapies (RPT) for some of the most difficult-to-treat cancers. Its growing pipeline includes novel RPT agents and companion diagnostic assets with the potential to provide curative responses for patients with advanced disease.

clinical trial designradioanalytical methodsradiolabelingradiopharmaceutical developmenttargeted radionuclide therapy

Augment Therapeutics is an early-stage pharmaceutical research and development company headquartered in Lake Forest, California, USA and Hyderabad, Telangana State, India. It develops 'Enhanced' versions of widely used off-patent generic drugs using proprietary novel linker/prodrug technologies, including its BINARS self-immolative linker platform, targeting development through the USFDA 505(b)(2) regulatory route.

clinical researchdrug discoveryprodrug/linker technology developmentregulatory affairs (US FDA 505(b)(2))

AyuVis Research is developing a platform of immunotherapies using novel small molecules to prevent and treat life-threatening diseases with no current effective therapies, including bronchopulmonary dysplasia (BPD) and pulmonary alveolar proteinosis (PAP). Its small molecules modulate white blood cells to fight inflammation and infection with a balanced immune response, are not hindered by drug resistance, and do not cause immunosuppression. The company reports extensive preclinical research with human clinical trials on the horizon.

immunotherapy researchsmall molecule drug development

Bound Therapeutics is a preclinical-stage biotechnology company developing RNA-based therapies for rare and refractory diseases, with a primary focus on oncology. Its proprietary Magic Bullet Designer (MBD) platform uses AI and machine learning to design tissue-targeted peptide ligands for RNA drug delivery. The company was founded in 2015 and is located at the Cambridge Innovation Center in Philadelphia, PA.

AI-driven drug discoveryde novo peptide ligand designmachine learningnanoparticle engineeringRNA therapeutics developmenttissue-targeted drug delivery

BrYet is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment and cure of otherwise incurable cancers, particularly metastatic cancers of the lungs and liver. It targets cancer-specific molecular transport phenotypes using multi-component therapeutics. Its first drug, ML-016, has demonstrated functional cures in preclinical animal models. Its research is protected by a patent portfolio, some licensed from Houston Methodist Research Institute and University of Texas Health Science Center at Houston.

drug developmentphenotype targeting

Cantargia AB is a Swedish listed biotechnology company that develops antibody-based therapies targeting the IL1RAP molecule for the treatment of cancer as well as inflammatory and autoimmune diseases. The company has brought two candidate drugs into clinical development, nadunolimab (CAN04) and CAN10, and develops a preclinical project CAN14 derived from its CANxx antibody platform. Cantargia was founded in 2010 by researchers Thoas Fioretos, Marcus Järås and Kjell Sjöström based on research from Lund University, and is listed on Nasdaq Stockholm's Main

antibody-based drug developmentbiomarker developmentclinical developmentcombination therapiesimmunotherapy

Cognitive Synergy Corporation is a biotechnology company developing novel small-molecule therapies for Alzheimer's disease and related neurodegenerative disorders. Its lead candidate is designed to restore synaptic health while reducing amyloid and tau pathology, aiming to be a disease-modifying treatment. The company integrates translational biomarkers, pharmacology, and behavioral outcomes and is progressing its small molecule through IND-enabling studies toward early clinical trials.

IND-enabling studiespharmacologysmall molecule drug discoverytranslational biomarkers

Common Pharma, Inc. is a pharmaceutical company developing medicine for hard-to-treat diseases. Its primary focus is a novel class of compounds with preclinical effectiveness in treating xenograft tumors and blocking IL-6 overexpression. Its patented molecules have shown anti-bacterial efficacy against P. Acne and MRSA, and it has a topical program for dermal conditions with clinical efficacy in reducing facial blemishes.

clinical trialsdrug development

Creative Bio-Peptides Inc. (CBP) is an early-stage biopharmaceutical company based in Rockville, MD, started in late 2017. It develops novel oral peptide immunotherapies, including receptor-active peptides (RAPs) such as lead compound RAP-103, for neurodegeneration, brain injuries, chronic pain, and substance use disorders.

oral peptide therapeuticspeptide drug development

Founded in 2021, Cryptobiotix is a preclinical research company that uses its ex vivo SIFR® technology pipeline to study how ingested actives are affected by digestion and interact with the gut microbiome and host. It provides gastrointestinal and gut microbiome research services, simulating the human GI tract and microbiome under biorelevant physiological conditions to deliver validated, predictive insights for clients in food, feed, biotech and pharma.

colonic fermentationdose-response analysisex vivo SIFR® technologygastrointestinal simulationgut microbiome researchhost-microbiome interaction modellingmode-of-action analysis

Dolinnov is a biotech company developing Precision Pump Modulators (PPMs), a novel class of non-opioid medicines for chronic pain. It is the first company worldwide to develop a lipid antisense oligonucleotide (L-ASO) therapy targeting FXYD2, a regulator of neuronal excitability in the DRG, to treat neuropathic and inflammatory chronic pain, including pain associated with rare diseases.

antisense oligonucleotide therapy developmentdrug discovery

Faeth Therapeutics is a clinical-stage oncology company pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway. Its lead candidate PIKTOR is an all-oral combination designed to inhibit PI3K-alpha, mTORC1, and mTORC2 simultaneously. The company was founded in 2019 and in February 2026 was acquired by Sensei Biotherapeutics, making PIKTOR the combined company's lead program.

clinical trialsdrug development

Immunartes is a biotechnology company developing therapies that neutralize Staphylococcus aureus immune evasion to restore host defense and prevent serious S. aureus disease. Its platform targets the immune-evasion pathway and supports coordinated vaccine and monoclonal antibody (mAb) programs aimed at prevention, currently in preclinical discovery and IND-enabling stages.

animal modelsantibody characterizationmonoclonal antibody developmenttranslational immunologyvaccine antigen evaluationvaccine development

Programming B Cells to Deliver Novel Therapies for Patients How We’re Doing It Immusoft is the world leader in engineering B cells as biofactories for therapeutic protein delivery, a novel approach that we have pioneered. Our platform, called Immune System Programming (ISP™) entails collecting a type of the patient’s immune cells, called B cells. In response to immune stimulation, B cells can turn into biofactories (known as plasma cells), each of which manufactures and secretes thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce personalized protein therapeutics. Once we have programmed the B cells, we then expand and differentiate into plasma cells that will then produce large amounts of our therapeutic protein. In the clinic, we then infuse the programmed cells back into the patient, where they take up.

B cell engineeringcell therapyclinical developmentplasma cell differentiation

Isofol Medical AB (publ) is a publicly listed clinical-phase biotechnology company developing the drug candidate arfolitixorin, which aims to increase the efficacy of standard treatments for patients with severe forms of cancer, with an initial focus on metastatic colorectal cancer. Its shares are traded on Nasdaq Stockholm.

clinical drug developmentclinical phase Ib/II studies

iSpine Ingenuity, Inc is a biotechnology startup founded in 2020 focused on early stage development of treatments for painful neuro-musculoskeletal conditions. It has initiated preclinical research to develop strategic treatments for unmet clinical needs such as degenerative discs, lumbar radicular pain, and osteoarthritis, and has completed pilot research investigating novel approaches for treating ailments that currently lack FDA approved regenerative treatments.

program development